



August 10, 2015

## GlycoMimetics to Present at the Canaccord Genuity Growth Conference

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that President & Chief Executive Officer Rachel King will present at the Canaccord Genuity Growth Conference in Boston on Wednesday, August 12, 2015 from 5:00 to 5:25 p.m. Eastern Time.

To access the live webcast and subsequent archived recordings for the presentation at the Canaccord conference, please visit the GlycoMimetics website at [www.glycomimetics.com](http://www.glycomimetics.com).

### About GlycoMimetics, Inc.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics entered into an exclusive license agreement with Pfizer for rivipansel in October 2011. Under the license agreement, Pfizer is responsible for the clinical development, regulatory approval and potential commercialization of rivipansel.

A GlycoMimetics wholly owned candidate therapy (GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

View source version on [businesswire.com](http://businesswire.com): <http://www.businesswire.com/news/home/20150810005861/en/>

GlycoMimetics, Inc.

#### Investor Contact:

Shari Annes, 650-888-0902

[sannes@annesassociates.com](mailto:sannes@annesassociates.com)

or

#### Media Contact:

Jamie Lacey-Moreira, 410-299-3310

[jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)

Source: GlycoMimetics, Inc.

News Provided by Acquire Media